Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has scheduled its H1 2025 financial results announcement for September 4, 2025.
The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT. The financial report will be accessible on Vivoryon's website, and participants can join via phone by pre-registering through the provided link or attend via live audio webcast.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), società clinica impegnata nello sviluppo di piccoli farmaci per patologie infiammatorie e fibrotiche, con particolare attenzione alle malattie renali, ha fissato la pubblicazione dei suoi risultati finanziari del primo semestre 2025 per il 4 settembre 2025.
La società terrà una conference call e una webcast alle 15:00 CEST / 09:00 EDT. Il rapporto finanziario sarà disponibile sul sito web di Vivoryon, e i partecipanti potranno intervenire telefonicamente previa registrazione tramite il link fornito o seguire la trasmissione audio in diretta.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), una compañía en fase clínica centrada en desarrollar medicamentos orales para trastornos inflamatorios y fibróticos, especialmente enfermedades renales, ha programado el anuncio de sus resultados financieros del primer semestre de 2025 para el 4 de septiembre de 2025.
La empresa organizará una conferencia telefónica y una retransmisión web a las 15:00 CEST / 09:00 EDT. El informe financiero estará disponible en la web de Vivoryon, y los asistentes podrán unirse por teléfono previa preregistración mediante el enlace proporcionado o seguir la retransmisión de audio en directo.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY)는 염증 및 섬유화 질환, 특히 신장 질환 치료를 위한 저분자 의약품 개발에 주력하는 임상단계 기업으로, 2025년 상반기 재무결과 발표를 2025년 9월 4일로 예정했습니다.
회사 측은 CEST 오후 3시 / EDT 오전 9시에 컨퍼런스 콜과 웹캐스트를 개최합니다. 재무보고서는 Vivoryon 웹사이트에서 확인할 수 있으며, 참가자는 제공된 링크로 사전등록 후 전화로 참여하거나 실시간 오디오 웹캐스트를 통해 참석할 수 있습니다.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), société en phase clinique dédiée au développement de petites molécules pour les affections inflammatoires et fibreuses, en particulier les maladies rénales, a programmé la publication de ses résultats financiers du premier semestre 2025 pour le 4 septembre 2025.
La société organisera une conférence téléphonique et une webdiffusion à 15h00 CEST / 09h00 EDT. Le rapport financier sera consultable sur le site de Vivoryon, et les participants pourront se joindre par téléphone après préinscription via le lien fourni ou écouter la diffusion audio en direct.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), ein klinisch tätiges Unternehmen, das sich auf die Entwicklung kleinmolekularer Medikamente für entzündliche und fibrotische Erkrankungen, insbesondere Nierenerkrankungen, konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das erste Halbjahr 2025 für den 4. September 2025 terminiert.
Das Unternehmen wird um 15:00 CEST / 09:00 EDT eine Telefonkonferenz und ein Webcast abhalten. Der Finanzbericht wird auf der Website von Vivoryon verfügbar sein; Teilnehmer können sich per Telefon nach vorheriger Registrierung über den bereitgestellten Link einwählen oder dem Live-Audio-Webcast folgen.
- None.
- None.
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Halle (Saale) / Munich, Germany, August 27, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its half year financial results for the period ended June 30, 2025 and provide a corporate update on Thursday, September 4, 2025. The Company will host a conference call and webcast open to the public. The report will be available for download on the Company's website (https://www.vivoryon.com/financial-information/).
Conference call details
Date: September 4, 2025
Time: 3:00 pm CEST / 9:00 am EDT
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon´s website at: https://www.vivoryon.com/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
https://register-conf.media-server.com/register/BI5a3854fa349d497f8979340542813a0f
It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When will Vivoryon Therapeutics (VVY) report its H1 2025 financial results?
How can investors access Vivoryon's (VVY) H1 2025 earnings call?
What is Vivoryon Therapeutics' (VVY) main business focus?
Where can investors find Vivoryon's (VVY) H1 2025 financial report?
